DAC
CBPO

Dymon Asia Capital’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Dymon Asia Capital’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-8,000
Closed -$916K – 13
2016
Q1 		$916K Buy
+8,000
New +$938K 0.69% 12

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dymon Asia Capital's CBPO Position: Q2 2016 in Review

Dymon Asia Capital sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2016, closing a stake of 8,000 shares — an estimated $916K sold.

Dymon Asia Capital first reported a position in CBPO in Q1 2016 and held it in 1 quarter. The position peaked at $916K in Q1 2016. 138 funds tracked by Wall St. Rank hold CBPO as of Q2 2016.

  • Dymon Asia Capital reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • Dymon Asia Capital sold 8,000 China Biologic Products Holdings, Inc. shares in Q2 2016, an estimated $916K.
  • Dymon Asia Capital first reported a position in China Biologic Products Holdings, Inc. in Q1 2016 and held it in 1 quarter.
  • Dymon Asia Capital's China Biologic Products Holdings, Inc. position peaked at $916K in Q1 2016.
  • 138 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2016.

Based on Dymon Asia Capital's 13F filing for Q2 2016, filed 12 Aug 2016.